Allogeneic hematopoietic stem cell transplantation for the treatment of BCR::ABL-negative neutrophilic myeloid neoplasms: a clinical analysis of 12 cases
- VernacularTitle:异基因造血干细胞移植治疗BCR::ABL阴性中性粒细胞增殖性肿瘤12例临床研究
- Author:
Tingting HAN
1
;
Yun HE
1
;
Jing LIU
1
;
Yao CHEN
1
;
Fengrong WANG
1
;
Jingzhi WANG
1
;
Yuhong CHEN
1
;
Haixia FU
1
;
Lanping XU
1
;
Xiaohui ZHANG
1
;
Xiaojun HUANG
1
;
Yu WANG
1
Author Information
- Publication Type:Journal Article
- Keywords: Allogeneic hematopoietic stem cell transplantation; Atypical chronic myeloid leukemia; MDS/MPN with neutrophilia; Chronic neutrophilic leukemia
- From: Chinese Journal of Hematology 2025;46(9):827-832
- CountryChina
- Language:Chinese
- Abstract: Objective:To investigate the efficacy and safety of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for the treatment of BCR::ABL-negative chronic neutrophilic leukemia (CNL) and MDS/MPN with neutrophilia.Methods:This study retrospectively analyzed 12 cases of CNL and MDS/MPN with neutrophilia that underwent allo-HSCT from March 2017 to June 2024, comprising 7 males and 5 females with a median age of 48 ( IQR: 28, 59) years. The 2-year overall survival (OS), disease-free survival (DFS), cumulative incidence of relapse (CIR), and transplantation-related mortality (TRM) rates were analyzed. Complications were also assessed. Results:Of the 12 patients, 6 received matched sibling HSCT and 6 received haploidentical HSCT. All patients had successful engraftment, and the median times of neutrophil and platelet engraftment were 17 ( IQR: 11, 24) days and 15 ( IQR: 9, 28) days, respectively. Grade Ⅱ–Ⅳ acute graft versus host disease (GVHD) and chronic GVHD occurred in 2 and 4 cases, respectively. The 2-year OS, DFS, CIR, and TRM rates were (65.6 ± 16.4) %, (41.7 ± 16.6) %, (47.2 ±18.2) %, and (11.1 ± 11.4) %, respectively, after a median follow-up time of 637 ( IQR: 330, 943) days. One patient died from treatment-related complications due to respiratory failure caused by coronavirus disease 2019. Two patients died due to relapse. Conclusion:Allo-HSCT can be applied as a safe and effective approach to treat CNL and MDS/MPN with neutrophilia.
